Daniel Getts, Ph.D.

Daniel Getts is a global leader in RNA therapeutics and immune engineering. He is the founder and CEO of CREATE Medicines, a clinical-stage biotech pioneering in vivo mRNA immune cell programming.

Throughout his career, Getts has founded or co-founded several biotechnology companies, including Cour Pharmaceuticals, the field leader in immune tolerance, striking major partnerships with Takeda ($420M) and Genentech ($940M). Collectively, his ventures have generated more than $2 billion USD in value and advanced 11 novel therapies into clinical trials across cancer, autoimmune disease, and transplant rejection.

Born and raised in a working-class family in southern Sydney, Getts earned his Ph.D. in Medicine from the University of Sydney and his MBA from Western Michigan University. He was a research professor at Northwestern University, where he co-invented multiple immune modulation platforms.

Dr. Getts serves as an advisor to governments and health agencies in the US, Europe, and Asia, and has spoken at international forums including the World Economic Forum, World Government Summit, and the BIO International Convention. He participates in international policy and industry think tanks shaping policy in biotechnology, health security, and advanced manufacturing.

Getts holds over 200 patents and has published extensively in top peer-reviewed journals, including Nature Biotechnology and Science Translational Medicine.